HDAC1, a novel marker for benign teratomas.


Histone deacetylases (HDACs) are non-redundant chromatin-modifying enzymes that are critical cellular regulators and are often overexpressed in cancers. Targeting them by HDAC inhibitors (HDACis) can induce growth arrest, differentiation or apoptosis, making HDACi agents promising anti-cancer drugs, and these are currently being tested in clinical trials… (More)
DOI: 10.1038/emboj.2010.281


1 Figure or Table